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Abstract 
Background: Sleep disorders are common in psychiatric diseases. Panic disorder (PD) and generalized anxiety disorder (GAD) are two major anxiety disorders 
that are associated with sleep disorders. Objective: We hypothesized that poor sleep quality continues in PD and GAD during remission. Therefore, in this 
study we aimed to compare the sleep quality of patients with PD and GAD to that of healthy controls. Methods: The study included patients with PD (n = 42) 
and GAD (n = 40) who had been in remission for at least 3 months and healthy control volunteers (n = 45). The patients were administered the Pittsburgh Sleep 
Quality Index (PSQI), Beck Anxiety Inventory (BAI), and Beck Depression Inventory (BDI). Results: The total PSQI scores of the GAD group were significantly 
increased in comparison to those of the PD (p = 0.009) and control (p < 0.001) groups. The rate of poor sleep quality in GAD during remission (77.5%) was 
greater than that of the PD (47.6%) and control (51.1%) groups (p = 0.011). Discussion: GAD is a chronic and recurrent disease. In this study, it was found that 
the deterioration in sleep quality of patients with GAD may continue during remission. In the follow-up and treatment of patients, it is appropriate to question 
about sleep symptoms and to plan interventions according to these symptoms.
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Introduction
Among the anxiety disorders, panic disorder (PD) and generalized 
anxiety disorder (GAD) are two diseases for which patients frequently 
visit the clinics. The overall prevalence of anxiety disorders is 
estimated to be 28.8%. The estimated prevalence of PD and GAD 
have been reported as 4.7% and 5.7%, respectively1. In some studies, 
GAD and specific phobias are the two most common anxiety 
disorders2. Anxiety disorders were the sixth leading cause of disability 
in countries of both high and low-middle socioeconomic status. 
The global burden of disease approach uses the disability-adjusted 
life year (DALY), and globally, anxiety disorders accounted for 390 
DALYs per 100,000 persons3. 
In PD and GAD, anxiety may give rise to physical signs and 
cognitive symptoms such as attention and concentration impairment 
and sleep disruption. The symptoms and signs of anxiety and sleep 
disorders frequently overlap. The sleep disorder may be a preliminary 
indication of anxiety, as well as a risk factor for developing an anxiety 
disorder4. In recent years there has been a shift towards assessing 
the overall impact of illness on the aspects of quality of life (QoL). 
Determining the effects of diseases on the quality of life and applying 
treatments for them has become more important. Sleep disorders 
and poor sleep quality adversely affect QoL5,6. The sleep disorders are 
quite prevalent and accompany various psychiatric diseases7,8. Poor 
physical health adversely impacts mental health and quality of life9-11. 
Sleep disturbance is commonly observed in individuals with 
anxiety disorders12. Compared to healthy controls, those with PD 
exhibit increased sleep onset latency, decreased sleep efficiency, 
decreased total sleep time, and many altered components of 
sleep4,8,12,13. A prevalence of 77% for restless and disturbed sleep and 
68% for difficulties in falling asleep has been reported in patients 
with PD8. Individuals with GAD exhibit decreased total sleep 
time, increased sleep onset latency, and variations in non-rapid eye 
movement (NREM) sleep12. Insomnia is recognized as a serious and 
significant health problem in patients with GAD14. More consistent 
findings on sleep disturbance in GAD have been reported, and 
sleep disturbance is included in the GAD diagnostic criteria15. The 
signs and symptoms of a sleep disorder are frequently experienced 
when the anxiety of PD or GAD is intense11. Characteristic 
polysomnographic findings are present in both diseases8. Hoge et 
al. hypothesized that amongst individuals with PD, higher anxiety 
sensitivity would be associated with sleep disruption, particularly 
in the form of increased sleep latency16. Higher anxiety sensitivity 
involves increases in attention and fearfulness about anxiety itself, 
and its associated physical sensations, which in turn may cause 
excessive arousal. Similar mechanisms may also be a cause of sleep 
disturbance in GAD. A day-long episode of anxiety in GAD may 
lead to stimulation that further causes sleep disruption. Despite all 
this information, the cause of sleep disorder in both PD and GAD 
is not known.
The period of remission in psychiatric diseases is defined as a 
notable reduction in signs and symptoms of the disease, or a nearly 
total resolution. Considering the recurring characteristics of PD and 
GAD, some signs and symptoms may persist in the remission period. 
There are many studies which have assessed the quality of sleep 
during the period when PD and GAD are uncontrolled. However, to 
the best of our knowledge, there is no study that assesses the quality 
of sleep in PD and GAD during remission and compares them to 
healthy controls. As is the case with many psychiatric diseases, the 
residual symptoms present in the period of improvement affect 
the ability of the patients to fully resume their pre-disease status 
and functionality. Improvement in residual symptoms, other than 
the main symptoms of anxiety, may significantly contribute to the 
feeling of wellness and functionality of the individuals. This study 
aimed to assess the quality of sleep of patients with PD and GAD 
during remission and to compare the assessment with that of healthy 
controls. In this study, our hypothesis was that (1) sleep quality is 
poorer in PD and GAD patients than in healthy controls; and (2) 
because GAD is more chronic, its sleep quality deterioration would 
be higher than in PD.
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Methods
This was a cross-sectional, case-control study. The study included 
patients with the diagnosis of PD and GAD according to the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-5) 
diagnostic criteria1. They had presented to the psychiatry clinic of 
the Faculty of Medicine Hospital of Yozgat Bozok University and 
were followed up in the same clinic by two specialized physicians 
(YH, OK). Included in the study were patients aged 15-65 years, with 
no additional psychiatric disease, who had been in remission from 
PD or GAD for no less than 3 months, who were cognitively able 
to complete the test (Ÿdid not have difficulty in understanding the 
self-reported questionnaires), and who scored 9 or lower on the BDI 
and 7 or lower on the BAI. A clinical examination was performed, 
and patients with a BAI score of 7 or less at the time of the study 
and within the last 3 months according to hospital records were 
determined to be in remission. Regarding their treatments, only 
patients in whom selective serotonin reuptake inhibitors (SSRIs) 
or serotonin and norepinephrine reuptake inhibitors (SNRIs) had 
been prescribed were included. The control group was comprised 
of medical personnel employed in the same hospital and patients’ 
relatives who were free of any physical or psychiatric ailment or 
known sleep disorder. For each participant, depression levels were 
evaluated by means of the Beck Depression Inventory (BDI), anxiety 
levels by means of the Beck Anxiety Inventory (BAI), and quality of 
sleep by means of the Pittsburgh Sleep Quality Index (PSQI). Those 
with chronic physical diseases, those with physical or psychiatric 
diseases that may cause sleep disorder, users of benzodiazepines and/
or stimulants, those with an alcohol abuse disorder, and pregnant 
persons were excluded. A total of 167 persons were included (42 with 
PD, 40 with GAD, and 45 healthy controls) (Figure 1).
The participants were informed about the study, and written 
informed consent was obtained from all participants before their entry. 
The study was approved by the local Ethics Committee of Yozgat Bozok 
University, with a protocol number of 2017-KAEK-189_2018.05.16_05, 
and it was performed under the ethical principles of the Declaration 
of Helsinki for medical research involving human subjects.
Assessment tools
Data collection form
This form was prepared by the researchers and contains information 
such as age, gender, education, smoking status, and height and weight 
of the participants. 
Pittsburgh Sleep Quality Index (PSQI)
The PSQI was developed by Buysse et al.17, and the Turkish validity 
and reliability study was conducted by Ağargün et al.18. The PSQI is 
a 19-item self-report scale that assesses sleep quality and disturbance 
over the past month. It consists of 24 questions, of which 19 involve 
self-assessment and 5 are answered by his or her sleep partner. The 
18 questions scored in the scale consist of 7 components: subjective 
sleep quality, sleep latency, sleep duration, habitual sleep efficiency, 
sleep disturbance, use of sleep medications, and daytime dysfunction. 
Each component is rated from 0 to 3 points. The total score is the 
sum of the 7 subscales’ scores. The total PSQI score ranges between 
0 and 21 points. A high total PSQI score indicates poor sleep quality 
and severe sleep disturbance. A total PSQI score of over 5 points 
indicates clinically poor sleep quality.
Beck Depression Inventory (BDI)
The BDI was developed by Beck et al.19 to evaluate the physical, 
emotional, cognitive, and motivational symptoms seen in depression. 
The BDI is a scale consisting of 21 self-evaluation sentences, and each 
symptom category has four options. Each item is scored between 
0 and 3 points, and the total score ranges from 0 to 63 points. In 
terms of the severity of depressive symptoms, 0 to 9 points indicates 
minimal symptoms. The Turkish validity and reliability study was 
performed by Hisli et al.20.
Beck Anxiety Inventory (BAI)
The BAI was developed by Beck et al.21 to assess the extent of an 
individual’s anxiety symptoms. Based on self-reporting, the BAI 
consists of 21 items, and each item is scored between 0 and 3 points. 
The total score ranges from 0 to 63 points. The total score obtained 
from the scale indicates the severity of the individual’s anxiety. The 
Turkish validity and reliability study was carried out by Ulusoy et al.22.
Statistical analysis
Statistical analysis was performed using the SPSS 22.0 (Statistical 
Package for Social Sciences, IBM Inc., Chicago, IL, USA) package 
program. The descriptive statistics for the data were calculated, and the 
Kolmogorov–Smirnov methods were applied for testing the normality 
distribution. The chi-square test was used for comparison of groups 
with respect to the categorical variables. ANOVA and the post hoc 
Tukey test were applied to the 3-group comparison of the data which 
exhibited normal distribution. The Kruskal-Wallis H test was used for 
group comparisons of non-parametric variables, and omnibus effects 
were explored using the Mann-Whitney U test to determine which 
pairs of groups differed. p significance was determined by dividing 
the significance value by the number of groups. The Bonferroni 
correction for multiple comparisons was used (0.05/3=0.016). The 
Pearson’s correlation test was used for the normally distributed data, 
and the Spearman’s correlation test was used for data not showing 
a normal distribution. A regression model was established for the 
variables showing significant correlation, and diagnostic tests of this 
model were carried out. A p value of less than 0.05 was considered 
statistically significant. After the evaluation of previous study results, a 
power analysis was performed. The alpha and beta errors were stated, 
respectively, as 0.05 and 0.20. The minimum number of patients 
needed to obtain 80% power was calculated as 34 for each group.
Results
The average age in the PD group was 44.38 ± 13.58 years; in the 
GAD group it was 47.28 ± 10.76 years, and in the control group 
it was 41.51 ± 10.46 years. No significant differences appeared 
in terms of age, gender, and smoking habits between the groups 
(p > 0.05). The body mass indexes (BMIs) of the GAD and PD groups 
were significantly higher compared to that of the control group Figure 1. Flow chart of participants.
Groups
Reached participants
PD GAD Control
n= 64 n= 63 n= 59
Non-participants n= 12 n= 14 n= 8
Incompleted survey n= 4 n= 6 n= 2
Included in the study 
PD: panic disorder; GAD: generalized anxiety disorder.
n= 42 n= 40 n= 45
Participants with
other disorders 
that may cause
sleep disturbance
n= 6 n= 7 n= 4
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(p < 0.001). The duration of disease for the PD group was significantly 
higher than that of the GAD group (p < 0.001) (Table 1). There was 
no statistically significant difference between the PD and GAD 
groups in terms of the medications used by the participants (p = 
0.258) (Table 2). 
Although the BDI and BAI scores of the patients in the PD and 
GAD groups remained within normal limits, they are significantly 
higher with reference to the control group (p < 0.001). The difference 
among the three groups in terms of total PSQI scores was statistically 
significant (p < 0.001). Pairwise comparisons conducted in order to 
determine the source of the difference revealed statistically higher 
significance for the total PSQI scores of the GAD group compared 
to the PD and control groups (p = 0.009; p < 0.001, respectively). 
When the sleep quality was assessed as poor for those having a total 
PSQI score higher than 5, the sleep quality of 77.5% (n = 31) of the 
patients with GAD, 47.6% (n = 20) of the patients with PD, and 51.1% 
of the control group patients (n = 23) was poor, and the difference 
was statistically significant (p = 0.011). After pairwise comparisons, 
the proportion of GAD patients having poor sleep was significantly 
higher compared to the PD and control groups (p = 0.005; p = 0.012, 
respectively). The difference between the PD and control groups was 
not statistically significant (p > 0.05) (Table 3). When a post hoc 
power analysis was applied with alpha 0.05, the power of the study 
was found to be 0.9885.
Table 1. Evaluation of demographic features by groups
Groups Test Value
PD (n = 42) GAD (n = 40) Controls (n = 45) p
Age Mean ± SD 44.38 ±13.58 47.28 ± 10.76 41.51 ± 10.46 F: 2.584
Min-Max 22 - 65 23 - 65 24 - 63 0.080a
BMI Mean ± SD 29.26 ± 5.54d 30.13 ± 4.67d 26.02 ± 5.15 F: 8.544 **<0.001a
Smoking Mean ± SD (number/day) 16.43 ± 11.63 12.44 ± 7.58 13.21 ± 8.55 F: 0.592 0.559a
Duration of disease 
(months)
Mean ± SD
Min-Max (Median)
67.29 ± 8.61
5-240 (48)e
47.58 ± 8.48
12-240 (22)
-- Z: -2.321
*0.020b
n (%) n (%) n (%)
Gender Female 24 (57.1) 26 (65.0) 26 (57.8) χ2: 0.650
Male 18 (42.9) 14 (35.0) 19 (42.2) 0.723c
Smoking Smokers
Non-smokers
14 (33.3)
28 (66.7)
9 (22.5)
31 (77.5)
14 (31.1)
31 (68.9)
χ2: 1.297
0.523c
* p < 0.05. ** p < 0.01. a ANOVA. b Mann-Whitney U test. c Pearson Chi-Square test. d Significantly higher than in the control group; e Significantly higher than in the GAD group. PD: panic disorder; 
GAD: generalized anxiety disorder; BMI: body mass index.
Table 2. Medications used by patients
Groups Test Value
PD (n = 42) GAD (n = 40) χ2 p
SSRIs 78.6% (n = 33) 67.5% (n = 27) 1.279 0.258
Escitalopram 16 13
Sertraline 7 5
Paroxetine 6 4
Fluoxetine 3 1
Citalopram 2 2
Fluvoxamine - 1
SNRIs 21.4% (n = 9) 32.5% (n = 13)
Duloxetine 4 9
Venlafaxine 5 4
χ2: Chi-square value; PD: panic disorder; GAD: generalized anxiety disorder; SSRIs: selective serotonin reuptake inhibitors; SNRIs: serotonin and norepinephrine reuptake inhibitors.
Table 3. Evaluation of scores of Beck Depression Scale, Beck Anxiety Scale, and Pittsburgh Sleep Quality by groups
Groups Test Value
PD (n = 42) GAD (n = 40) Control (n = 45) p
BAI
Min-Max (Median)
Mean ± SD
5-7 (6)b 4-7 (5)b 2-5 (4) χ2: 84.562
5.86 ± 0.75 5.58 ± 0.74 3.56 ± 0.72 **<0.001a
BDI 
Min-Max (Median)
Mean ± SD
4-6 (5)b 3-6 (4)b 2-4 (3) χ2: 84.677
4.86 ± 0.75 4.58 ± 0.55 2.60 ± 0.65 **<0.001a
PSQI
Min-Max (Median)
Mean ± SD
0-12 (5) 0-17 (9)c 0-15 (6) χ2: 15.591
6.52±3.74 9.0 ± 4.09 5.64 ± 3.21 **<0.001a
Sleep Quality n (%) n (%) n (%)
Good 22 (52.4) 9 (22.5) 22 (48.9) χ2: 8.991
Poor 20 (47.6) 31 (77.5)c 23 (51.1) *0.011d
* p < 0.05. **p < 0.01. a Kruskal-Wallis test. b Significantly higher than in the control group. c Significantly higher than in the PD group and control group. d Pearson Chi-Square test.
BAI: Beck Anxiety Scale; BDI: Beck Depression Scale; PSQI: Pittsburgh Sleep Quality Index; PD: panic disorder; GAD: generalized anxiety disorder.
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Analysis of the sub-components of the PSQI demonstrated a 
significant difference in terms of subjective sleep quality (p = 0.008), 
sleep latency (p < 0.001), sleep duration (p < 0.001), habitual sleep 
efficiency (p = 0.027), use of sleep medications (p = 0.014), time 
spent in bed (p = 0.049), and sleep duration (p < 0.001) (Table 4). 
When pairwise comparisons were conducted to find out the source 
of differences, the subjective sleep quality (Z: -2.793; p = 0.005), 
sleep duration (Z: -4.002; p < 0.001), and habitual sleep efficiency 
(Z: -2.589; p = 0.01) scores of patients with GAD were significantly 
higher compared to those of the PD group. The scores for subjective 
sleep quality (Z: -2.508; p = 0.012), sleep latency (Z: -3.762; p < 0.001), 
and use of sleep medications (Z: -1.255; p = 0.005) were significantly 
higher in GAD patients than in controls. The sleep latency (Z: 
-3.450; p = 0.001), sleep duration (Z: -2.997; p = 0.003), and use of 
sleep medications (Z: 2.651; p = 0.008) of the patients with PD were 
significantly higher than in the control group.
In all participants evaluated together, there were positive 
correlations between the total PSQI scores and BMI (r: 0.247; 
Table 4. Evaluation of scores of Pittsburgh Sleep Quality Index sub-components between groups
Groups Test Value
PD (n = 42) GAD (n = 40) Control (n = 45) pa
Subjective Sleep Quality
Min-Max (Median) 0-3 (1) 0-3 (2)b,c 0-3 (1)
χ2: 9.708
0.008**
Sleep Latency
Min-Max (Median) 0-3 (2)b 0-3 (3)b 0-3 (2)
χ2: 18.610
<0.001**
Sleep Duration
Min-Max (Median) 0-3 (0)b 0-3 (1)c 0-3 (1)
χ2: 18.618
<0.001**
Habitual Sleep Efficiency χ2: 7.201
Min-Max (Median) 0-2 (0) 0-3 (1)c 0-3 (0) 0.027*
Sleep Disturbances χ2: 2.325
Min-Max (Median) 0-2 (1) 0-3 (1) 0-2 (1) 0.313
Use of Sleep Medication χ2: 8.527
Min-Max (Median) 0-3 (0)b 0-3 (0)b 0-2 (0) 0.014*
Daytime Dysfunction χ2: 5.534
Min-Max (Median) 0-3 (1) 0-3 (1) 0-3 (1) 0.063
Duration in Bed
Min-Max (Median) 4-12 (9)b 4-11 (7.75) 5.5-11 (7.5) χ2: 6.045
Avg. ± SD 8.31 ± 0.25 7.73 ± 0.23 7.72 ± 0.16 0.049*
Sleep Duration (hours)
Min-Max (Median) 4.5-8 (8)b,d 4.5-8 (6.5) 4.5-8 (6.5) χ2: 18.618
Avg. ± SD 7.28 ± 0.15 6.25 ± 0.17 6.67 ± 0.14 <0.001**
Sleep Percentage (sleep duration/
duration in bed)
Min-Max (Median) 66.7-99 (88.9) 50-99 (81.2) 40.9-99 (86.6) χ2: 3.387
Avg. ± SD 87.65 ± 1.40 81.85 ± 2.16 86.28 ± 1.63 0.184
* p < 0.05. ** p < 0.01. a Kruskal-Wallis Test. b Significantly higher than in the control group. c Significantly higher than in the PD group. d Significantly higher than in the GAD group. PD: panic disorder; 
GAD: generalized anxiety disorder.
p = 0.005), the number of cigarettes smoked daily (r: 0.422; p = 0.009), 
BAI score (r: 0.201; p = 0.023), and BDI score (r: 0.204; p = 0.021) 
(Table 5). When correlation analysis was performed in each group, 
there were positive correlations between the total PSQI scores and 
BMI (r: 0.314; p = 0.035) and the number of cigarettes smoked daily 
(r: 0.799; p = 0.001) only in the control group. In multiple regression 
analysis, the effect of daily cigarette smoking on the total PSQI 
level was 66.9% in healthy control patients (F [1,13] = 27.264; p < 
0.001). A negative correlation existed between the total PSQI scores 
and duration of disease in the patient group (r: -0.350; p = 0.001). 
When correlation analysis was performed in each patient group, the 
correlation between the total PSQI scores and the duration of disease 
was not significant (p > 0.05).
In multi-linear regression analysis, the evaluation of daily number 
of cigarettes, BMI, BAI score, and BDI score on the total PSQI scores 
revealed a statistically significant effect for daily number of cigarettes 
(Beta: 0.425; t: 2.731; p = 0.010).
Table 5. Review of correlation among Pittsburgh Sleep Quality Index, Beck Anxiety Scale, Beck Depression Scale, body mass index, daily cigarette con-
sumption and duration of disease 
PSQI
r p
All Groups
BAI 0.201 0.023*
BDI 0.204 0.005**
BMI 0.247 0.005**
Daily cigarette consumption 0.422 0.009**
PD and GAD group
Duration of disease -0.350 0.001**
r = Spearman’s correlation coefficient. * p < 0.05. ** p < 0.01. PSQI: Pittsburgh Sleep Quality Index; BAI: Beck Anxiety Scale; BDI: Beck Depression Scale; BMI: body mass index; PD: panic disorder; 
GAD: generalized anxiety disorder.
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Discussion 
In this study, even though the depression and anxiety levels of the 
patients with PD and GAD remained within normal limits, they were 
higher than in the control group. The sleep quality of the patients with 
GAD proved poorer in comparison to the PD and control groups. 
The sleep quality of the PD and GAD groups was poorer compared 
to the control group with respect to many sub-components of the 
PSQI. A collective evaluation of all groups suggests that smoking, 
increased age, and increases in BMI adversely affect sleep quality. 
Those with lesser duration of disease also have poorer sleep quality.
Anxiety and fear result in an increase in cortical and peripheral 
stimulation. Anxiety affects sleep, influencing the hypothalamic-
pituitary-adrenal axis and various other systems23. Stimulation also 
occurs in the case of any disorder that adversely affects starting and 
sustaining sleep. In general, a mutual interaction exists between 
anxiety and sleep disorder. The existence of either boosts the effect 
of the other24,25.
Chronic anxiety and strain comprise the basic features of GAD. 
GAD is associated with difficulty in starting and sustaining sleep4,15. 
Sleep disorder is more highly associated with GAD than with PD4. 
Extreme anxiety or worried expectation, the basic features of GAD 
play a significant role in the emergence and persistence of sleep 
disorders26. Certain studies have found that the prevalence of sleep 
disorders in patients with GAD is 50% to 85%, and such disorders 
are observed in various stages of sleep8,14,27. It is further known that 
if GAD symptoms are more severe, the prevalence of insomnia is 
higher28. The main finding of this study is that the sleep quality of 
patients with GAD in remission is lower compared to the individuals 
in the PD and control groups. Furthermore, subjective sleep quality, 
sleep duration, and habitual sleep efficiency in GAD patients was 
lower than in the PD group. In addition, subjective sleep quality, 
sleep latency, and daytime dysfunction were worse in GAD patients 
compared to the controls. The results of our study indicate that the 
adverse effects of GAD on sleep may persist despite the improvement 
in signs and symptoms of anxiety during the period of remission. 
This fact may be interpreted in a manner where the chronic and 
recurring feature of GAD and signs of sleep disorder survive in 
spite of a decline in signs of anxiety or meliorate in a longer term 
as compared to the signs of anxiety. In the study of Ramsawh et al., 
the strongest relationship between sleep disorder and anxiety was 
discovered in the GAD group11. The sleep disorder in patients with 
GAD may be observed in the form of residual signs, as is the case with 
numerous chronic psychiatric diseases. In our study, we determined a 
proportion of GAD patients with poor sleep quality (77.5%), and this 
percentage was just as high as it was during the peak attacks of the 
disease. This demonstrates that the sleep quality of patients with GAD 
does not improve even if the symptoms of anxiety are in remission.
Although certain studies have concluded that sleep disorder is 
more common in patients with PD than in healthy controls, there 
are other studies in which this is not addressed4,8. The panic attacks 
experienced during sleep may lead to insomnia by instilling fear in 
the individuals. One of the factors affecting the sleep disorder in 
PD is the presence of depression. Although the total PSQI scores of 
the patients with PD were similar to those of the control group, the 
sub-components, namely sleep latency, sleep duration, use of sleep 
medications, and duration in bed, were higher than in the control 
group. This result shows that sleep quality in patients with PD is poor 
in certain respects. The patients in our study did not have any panic 
attacks, since they were in remission. Moreover, any patients with 
past and current depression had been excluded.
The medications used in the treatment of anxiety disorders may 
also impact sleep quality. However, the patients with PD and GAD 
in our study exhibited similar features in terms of the medications 
that they used. 
Smoking is considered one of the significant factors having an 
impact on sleep quality. It is common knowledge that smoking has 
adverse effects on sleep for different reasons. The number of cigarettes 
smoked daily is the most important factor that harms sleep quality29,30. 
In our study, with all participants evaluated together, there was a 
positive correlation between total PSQI scores and the number of 
cigarettes smoked daily. However, when correlation analysis was 
performed in each group, there was a positive correlation only in 
the control group between PSQI scores and the number of cigarettes 
smoked daily. The effect of daily cigarette smoking on poor sleep 
quality was approximately 67% in healthy controls.
The sleep pattern is known to vary with age, and insomnia 
increases with age. Our study also determined that sleep quality 
deteriorates with age. This result is consistent with the body of 
literature31. 
High BMI may adversely affect many systems, from metabolic 
issues to the respiratory tract. Sleep quality worsens owing to such 
effects32. In our study, as BMI increased, the sleep quality worsened.
The poorer sleep quality in those individuals with shorter disease 
duration may be due to experiencing more sleep disruption in the 
initial periods of the disease due to acute anxiety. The sleep disorder 
may improve if the patients develop mechanisms to cope with the 
problem in time.
Sleep disorder gives rise to significant losses of functionality in 
daily life. The significant sleep disorders associated with GAD are 
not fully healed. It has been demonstrated that individuals with 
anxiety disorders and poor sleep have significantly worse mental 
health-related quality of life and increased disability compared to 
those with anxiety disorders alone11. Although the symptoms of 
anxiety improve during the periods of wellness in the patients with 
PD and GAD, the other residual symptoms can persist. In PD and 
GAD, disruption with respect to some areas of sleep, in addition to 
overall deterioration of sleep quality, is more common. 
The fact that this study is cross-sectional, with a small number 
of participants, serves as a significant limitation. Although the PSQI 
is a validated sleep quality scale, it alone is not sufficient for the 
evaluation of sleep quality and the sub-components of sleep disorders. 
In larger sample groups, the quality of sleep should be evaluated by 
more objective tests, such as actigraphy or polysomnography, and 
follow-up studies should further be conducted. Caffeine intake may 
affect sleep quality. Participants weren’t asked about their amounts 
of caffeine and black tea intake.
Consequently, the sleep disorder is an important component 
of anxiety disorders. Although treatments aimed at the primary 
disease may result in improved symptoms, this result itself is not 
sufficient. The sleep disorder in patients with GAD may persist 
despite adequate treatment of the anxiety symptoms. Enquiring about 
sleep disorder in patients with GAD in remission, and administering 
pharmacologically and non-pharmacologically specific treatments 
intended for this purpose, is of great importance.
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